By admin 
CureSearch for Children’s Cancer, a leading national non-profit organization dedicated to accelerating the development of new treatments for pediatric cancer, has officially announced the appointment of Osama Alsaleh to its Board of Directors. The addition of Alsaleh, a prominent figure in the global healthcare innovation and venture capital landscape, marks a strategic effort by the organization to bridge the gap between clinical research and commercial investment. With a career defined by high-impact roles at the intersection of technology, health equity, and strategic partnerships, Alsaleh is expected to play a pivotal role in expanding CureSearch’s reach into the private sector and venture ecosystems.
The appointment comes at a critical juncture for pediatric oncology, a field that has historically struggled with a lack of private-sector investment compared to adult oncology. Alsaleh currently serves as the Head of Partnerships at Plug and Play Health, which is recognized as one of the world’s most active venture capital firms and global innovation platforms. His background in identifying and scaling transformative healthcare technologies is seen as a vital asset for CureSearch as it seeks to navigate the complexities of the "Valley of Death"—the notorious gap in funding that occurs between laboratory discovery and the commencement of clinical trials.
A Career Defined by Innovation and Global Health Impact
Osama Alsaleh’s professional trajectory provides a comprehensive view of the modern healthcare ecosystem. Before his current leadership role at Plug and Play Health, Alsaleh held significant positions at Oracle Health (formerly Cerner Corporation), where he was instrumental in shaping the company’s approach to global health initiatives and regulatory compliance. One of his most notable achievements was the conceptualization and launch of Oracle’s health equity team. This initiative focused on integrating social determinants of health (SDOH) into clinical workflows, ensuring that factors such as socioeconomic status, geography, and accessibility were considered in healthcare delivery and technology development.
His experience in financial stewardship and grant allocation is equally extensive. During his tenure at the Oracle Charitable Foundation Clinical Decision Committee, Alsaleh contributed to the evaluation and distribution of more than $42 million in healthcare grants. This experience provided him with a deep understanding of how philanthropic capital can be utilized to drive clinical progress, a skill set that aligns directly with CureSearch’s mission to fund high-impact translational research.
Beyond the private sector, Alsaleh has been a frequent advisor to government bodies and international organizations. His resume includes collaborations with the World Bank Group and the World Health Organization (WHO), as well as high-level advisory roles for the U.S. State Department. Notably, during the height of the global pandemic, he contributed his expertise to the White House COVID-19 Taskforce, advising on digital health responses and data-driven strategies to mitigate the crisis. His ability to navigate the regulatory landscape, including work with the Centers for Medicare & Medicaid Services (CMS) on quality reporting measures, positions him as a bridge-builder between innovators and policy makers.
Addressing the Funding Disparity in Pediatric Oncology
The strategic importance of Alsaleh’s appointment is underscored by the current state of pediatric cancer research funding. While cancer remains the leading cause of death by disease among children in the United States, the research and development (R&D) landscape for pediatric treatments faces significant hurdles. According to data from the National Cancer Institute (NCI), only about 4% of the federal budget for cancer research is specifically dedicated to childhood cancers.
This funding disparity is exacerbated by the economic realities of the pharmaceutical industry. Because pediatric cancers are relatively rare compared to adult cancers—such as breast, lung, or prostate cancer—the market incentive for major pharmaceutical companies to develop "pediatric-first" drugs is often lacking. Consequently, many children are treated with decades-old protocols or drugs that were originally designed and approved for adults, leading to severe long-term side effects and late-stage complications for survivors.
Alsaleh’s entrance into the CureSearch leadership structure is intended to address this systemic challenge. By leveraging his network within the venture capital and startup communities, CureSearch aims to attract "venture philanthropy" and private investment into the pediatric space. The goal is to treat pediatric oncology not just as a charitable cause, but as a frontier for high-tech innovation that can yield significant medical and societal returns.
Strategic Synergy: Venture Capital and Translational Research
In his statement regarding the appointment, Alsaleh highlighted the systemic neglect of pediatric innovation within mainstream investment circles. He noted that despite the rapid advancement of biotechnology and AI-driven drug discovery, pediatrics remains significantly underrepresented in the portfolios of global venture capital firms. His mission on the CureSearch board will be to "leveraging my network across venture capital, startups, healthcare institutions, and technology companies" to attract new resources and strategic partners.
Jared Brancazio, Chair of CureSearch’s Board of Directors, emphasized the value of this unique perspective. "Osama’s ability to connect innovation, investment, and healthcare will help expand our reach and unlock new opportunities to advance critical research for children with cancer," Brancazio stated. The organization believes that by integrating a venture-capital mindset, they can better identify which research projects have the highest potential for commercial viability and, therefore, the highest likelihood of reaching the patients who need them.
CureSearch has a long history of pivoting to meet the changing needs of the medical community. Originally founded in 1986 as a clinical trials network, the organization shifted its focus in recent years to translational research. This model prioritizes the "translation" of laboratory findings into actual treatments. By bringing in a leader from Plug and Play Health, CureSearch is signaling a further evolution toward an "innovation-first" model that utilizes global technology trends to solve the unique challenges of childhood cancer.
Chronology of Leadership and Organizational Evolution
The appointment of Osama Alsaleh is the latest in a series of strategic moves by CureSearch to modernize its approach to fighting pediatric cancer.
- 1986 – 2010: CureSearch operates as the primary funding arm for the Children’s Oncology Group (COG), the world’s largest organization devoted to pediatric cancer research.
- 2011 – 2015: Recognizing a shift in the funding landscape, CureSearch transitions to an independent model focusing on high-risk, high-reward translational research that federal grants often overlook.
- 2016 – 2022: The organization launches the "CureSearch Acceleration Initiative," specifically designed to fund research that has a clear path to clinical trials within three years. During this time, the board begins seeking more diverse expertise from the tech and finance sectors.
- 2023 – Present: CureSearch intensifies its focus on industry partnerships. The appointment of Alsaleh in 2024 represents a definitive move to integrate venture capital strategies into the nonprofit’s governance.
Broader Implications for Health Equity and Pediatric Care
Beyond the immediate goal of drug development, Alsaleh’s background in health equity suggests that CureSearch will also place a higher premium on ensuring that new treatments are accessible to all demographics. Pediatric cancer does not affect all populations equally; survival rates can vary based on a family’s proximity to specialized children’s hospitals and their ability to navigate complex insurance and clinical trial landscapes.
By applying the principles of social determinants of health to pediatric oncology, Alsaleh can help CureSearch develop strategies that ensure innovation does not outpace equity. This includes looking at how digital health tools, remote monitoring, and telemedicine—areas where Plug and Play Health is deeply invested—can be used to support families who live far from major metropolitan medical centers.
Furthermore, Alsaleh’s experience with the US State Department and the WHO suggests a potential expansion of CureSearch’s international influence. While the organization is based in the United States, the fight against childhood cancer is a global one. Strategic partnerships with international innovation hubs could allow CureSearch to foster cross-border research collaborations, accelerating the pace of discovery through shared data and resources.
Conclusion: A New Era for Pediatric Oncology Advocacy
The addition of Osama Alsaleh to the CureSearch Board of Directors reflects a growing trend in the nonprofit sector: the professionalization of philanthropy through the lens of venture capital and technological innovation. As the healthcare industry moves toward personalized medicine and genomics, the traditional "fundraising only" model is being replaced by a more active, strategic approach to R&D.
For the thousands of families currently battling pediatric cancer, this shift represents a renewed sense of hope. By bringing in leaders like Alsaleh, who understand the mechanics of the global investment economy, CureSearch is positioning itself to break the financial and regulatory logjams that have historically slowed progress. The integration of venture capital expertise, health equity focus, and a track record of global collaboration marks a new chapter for CureSearch as it continues its mission to find cures for the world’s youngest cancer patients.
